In other recent news, Avadel Pharmaceuticals reported a fourth-quarter 2024 revenue of $50.41 million, which fell short of the forecasted $52.48 million. The company also posted an earnings per share (EPS) of -$0.05, missing the expected -$0.02. Despite these misses, Avadel maintained its full-year 2025 revenue guidance of $240 million to $260 million, highlighting strong market penetration of its narcolepsy treatment, Lumryz. Analyst firms such as H.C. Wainwright and Oppenheimer have maintained positive outlooks on Avadel, with price targets set at $21.00 and $22.00 respectively, reflecting confidence in the company's growth strategy and potential revenue upside.